ArticlePharmaceutics2026

Phase III Study to Confirm Clinical Similarity of MB09, a Denosumab Biosimilar, and Prolia

Jerzy Supronik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.